Login
$TIL
$5.75 -$0.33 (5.43%) Live

Company Executives

Officer Age 2025 pay Source
Bronson Crouch Also a director
Chief Executive Officer and Chairman
53 $2,256,412
Sandeep Laumas
Chief Financial Officer and Chief Business Officer
58 $1,235,987

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Independent
4 of 5
stated in the proxy
Average tenure
6.5 years
from year joined
CEO also chairs the board
Yes
Bronson Crouch
Director Age On board Independent Other public boards 2025 pay Source
Bronson Crouch
53 Not stated Not independent None stated Paid as CEO
Neil Gibson
70 2020
6 years
Independent TCR2, Shattuck Laboratories, Causeway Therapeutics, Adanate Not stated
George Matcham
74 2018
8 years
Independent None stated Not stated
Gwendolyn Binder
51 2020
6 years
Independent None stated Not stated
R. Kent McGaughy, Jr.
54 2020
6 years
Independent None stated $211,671

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 24, 2026
Curative Ventures V LLC
holder of greater than 5% of our common stock; affiliate of Bronson Crouch, our Chief Executive Officer and Chairman
Amount not stated

Investors' rights, voting and right of first refusal agreement entered in connection with purchase of convertible preferred stock prior to IPO (registration rights, information rights and rights of first offer)

With Curative Ventures V LLC Open in proxy
Ibisbill, LP
holder of greater than 5% of our common stock; affiliate of R. Kent McGaughy, Jr., a member of our Board
Amount not stated

Investors' rights, voting and right of first refusal agreement entered in connection with purchase of convertible preferred stock prior to IPO (registration rights, information rights and rights of first offer)

With Ibisbill, LP Open in proxy
Vivo Capital Fund IX, L.P.
former holder of greater than 5% of our common stock; affiliate of Jack Nielsen, a former member of our Board
Amount not stated

Investors' rights, voting and right of first refusal agreement entered in connection with purchase of convertible preferred stock prior to IPO (registration rights, information rights and rights of first offer)

With Vivo Capital Fund IX, L.P. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support